Key facts
- It has raised $14.4M; the latest was Early Stage VC ($14.4M) in Feb 2026.
- Notable investors include Hefei Industry Investment Group, BOHE Angel Fund, BioTrack Capital, Hangzhou Tigermed Consulting Company, Huagai Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Punuozhiyao
- ·The full record, as it builds
Funding rounds
No funding rounds for Punuozhiyao are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Punuozhiyao
Researcher and provider of the drug intended to serve the biotechnology industry. The company is mainly focused on the research and development of AI-based drug design methods and chemical biology techniques to pioneer protein-protein interactions and develop innovative small molecules and degrader products, providing clients with industry-leading standard products and solutions.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Punuozhiyao doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Punuozhiyao shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Punuozhiyao in its N-PORT filings yet. We sweep new filings monthly.